Literature DB >> 3000427

Different forms of the epidermal growth factor receptor kinase have different autophosphorylation sites.

R E Gates, L E King.   

Abstract

Limited proteolysis converts the native (Mr 170 000) epidermal growth factor (EGF) receptor to the Mr 150 000 form of the receptor. Calcium-activated, neutral protease (purified to homogeneity from beef lung), chymotrypsin, and elastase were all similarly effective in generating the 150-kilodalton (150-kDa) form of the receptor in detergent-solubilized, membrane vesicles shed from A-431 cells. The rate of autophosphorylation with [gamma-32P]ATP of the 150-kDa form was only 10% of the rate with the native receptor. This decreased rate was not due to loss of kinase activity, since the phosphorylation of angiotensin was virtually unchanged after limited proteolysis of the native receptor kinase. However, maps of elastase-produced peptides from 170-kDa forms and elastase-generated 150-kDa forms of the EGF receptor showed that the major autophosphorylation sites in these two forms were totally different. Confirming this difference in autophosphorylation sites was the finding that the 32P label in the autophosphorylated native receptor could not be recovered in the 150-kDa form following proteolysis. This label was quantitatively recovered in 30-15-kDa peptide fragments generated simultaneously with the 150-kDa form of the receptor. Therefore, the decreased autophosphorylation of the 150-kDa form results from the loss of preferred autophosphorylation sites on the native receptor. Only 1-3% of the phosphate incorporated in the native receptor during autophosphorylation could be found on the 150-kDa autophosphorylation sites. Hence, autophosphorylation of the tyrosine sites in the 150-kDa form of the EGF receptor is markedly enhanced by removing the major sites autophosphorylated on the native form of the receptor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3000427     DOI: 10.1021/bi00340a038

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Identification of a novel autophosphorylation site (P4) on the epidermal growth factor receptor.

Authors:  J J Hsuan; N Totty; M D Waterfield
Journal:  Biochem J       Date:  1989-09-01       Impact factor: 3.857

2.  Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.

Authors:  Guolin Zhang; Bin Fang; Richard Z Liu; Huiyi Lin; Fumi Kinose; Yun Bai; Umut Oguz; Elizabeth R Remily-Wood; Jiannong Li; Soner Altiok; Steven Eschrich; John Koomen; Eric B Haura
Journal:  J Proteome Res       Date:  2010-12-03       Impact factor: 4.466

3.  Antitumor activity of a lectibody targeting cancer-associated high-mannose glycans.

Authors:  Young Jun Oh; Matthew W Dent; Angela R Freels; Qingwen Zhou; Carlito B Lebrilla; Michael L Merchant; Nobuyuki Matoba
Journal:  Mol Ther       Date:  2022-01-22       Impact factor: 12.910

4.  In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals.

Authors:  H Xie; T Turner; M H Wang; R K Singh; G P Siegal; A Wells
Journal:  Clin Exp Metastasis       Date:  1995-11       Impact factor: 5.150

5.  Epidermal-growth-factor-stimulated phosphorylation of calpactin II in membrane vesicles shed from cultured A-431 cells.

Authors:  J Blay; K A Valentine-Braun; J K Northup; M D Hollenberg
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

6.  Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis.

Authors:  P Chen; K Gupta; A Wells
Journal:  J Cell Biol       Date:  1994-02       Impact factor: 10.539

7.  Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer.

Authors:  V Ravery; M Colombel; Z Popov; S Bastuji; J J Patard; J Bellot; C C Abbou; Y Fradet; D K Chopin
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.